ACTA VETERINARIA ET ZOOTECHNICA SINICA ›› 2015, Vol. 46 ›› Issue (5): 824-829.doi: 10.11843/j.issn.0366-6964.2015.05.019

Previous Articles     Next Articles

Analysis of Immune Enhancement of Molecular Adjuvant CTLA-4 on IBDV VP2 Plasmid DNA

 WANG Yong-juan1,2,ZHU Shan-yuan2,LI Bi-chun1,HU Cheng2,ZUO Wei-yong2*   

  1. (1.College of Animal Science and Technology,Yangzhou University,Yangzhou 225009,China;2.Jiangsu Provincial Key Laboratory of Veterinary Bio-pharmaceutical High-tech Research,Jiangsu Animal Husbandry and Veterinary College,Taizhou 225300,China)
  • Received:2014-08-27 Online:2015-05-23 Published:2015-05-23

Abstract:

The study was conducted to evaluate the immune enhancement of molecular adjuvant CTLA-4 on IBDV VP2 plasmid DNA.Fusion protein mLTA-CTLA-4 and mLTA-VP2-CTLA-4 were expressed and purified based on vector pET-mLTA-CTLA-4 and pET-mLTA-VP2-CTLA-4.Protein toxicity tests were carried out on rabbits.10-day-old chickens were randomly divided into four groups,including different doses of mLTA-CTLA-4 plus IBD vaccine groups,different doses of mLTA-VP2-CTLA-4 groups,IBD live vaccine groups and control groups.Serum and mucosal samples were regularly collected for neutralization titer of IgG and IgA.After booster immunization,chickens were attacked by wild IBDV strain,and two weeks later protection rate were calculated.The results showed that levels of IgG and IgA in mLTA-VP2-CTLA-4 groups,mLTA-CTLA-4 with IBDV vaccine groups and conventional IBDV vaccine groups had no significant difference.IgG and IgA levels in mLTA-CTLA-4 with IBDV vaccine groups were slightly higher than that of mLTA-VP2-CTLA-4 groups.The protection rate was 100%.The results indicate that constructed IBDV molecular adjuvant DNA vaccine vector can express non-toxic recombinant protein,which can produce a good immune efficiency in chickens.It lays a foundation for further study on IBD subunit vaccine.

CLC Number: